\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes ERC EICThe calls for which deadlines will be extended for all applicants, irrespective of the country where the organisation is based, are the following:
The deadline for the EIC Accelerator cut-off for full (Step 2) proposals has been changed from 19 October to 8 November 2023 at 17:00 (CET).
At the same time, the 12-month limit to submit a full application following the successful evaluation of a short (Step 1) proposal is extended. Successful Step 1 applicants who exceed(ed) the maximum 12 months for submitting a full (Step 2) proposal between 7 June 2023 cut-off date and 8 November 2023 cut-off date, are allowed to submit a full (Step 2) proposal to the 8 November cut-off date. Funding and tender portal call topic pages
The new call deadlines for the EIC calls are visible on the European Commission Funding and tender portal already and for the ERC calls will be added soon.
More information on the background of this decision from the European Commission can be found in this European Commission DG Research and Innovation news article. The ERC and EIC each also published the news ERC news article and EIC news article
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
